Publications by authors named "T B Othman"
Cytomegalovirus reactivation (CMV-R) is a frequent complication post-allogeneic hematopoietic stem cell transplantation (allo-HSCT), associated with poor outcomes. Previous studies have demonstrated the protective effect of CMV-R against relapse after allo-HSCT for acute myeloblastic leukemia (AML). However, this impact remains unclear in acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFThe Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
J Natl Compr Canc Netw
October 2024
Article Synopsis
- CAR T-cell therapy is a novel treatment that has significantly improved outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
- There are two FDA-approved CAR-T products specifically for this condition: tisagenlecleucel for patients under 26 and brexucabtagene autoleucel for those 18 and older.
- The review discusses key clinical trials for these therapies, ongoing research addressing treatment strategies, and the potential future developments in CAR-T therapy to enhance patient care.
Article Synopsis
- - The study analyzed data from 245 patients who underwent allogeneic hematopoietic stem cell transplantation between 2016 and 2021, focusing on early bacteremia, defined as blood infections occurring within the first 100 days post-transplant.
- - Out of 40 cases of early bacteremia found, the majority were caused by gram-negative bacteria (62.5%), specifically Klebsiella and Pseudomonas species, with a high incidence (72.5%) occurring within the first 30 days post-transplant.
- - Key risk factors for developing bacteremia included using bone marrow as the graft source and cytomegalovirus reactivation, with a notable increase in multidrug-resistant strains observed among the
Article Synopsis
- Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk type of B-cell ALL that is difficult to treat effectively with standard therapies, resulting in poor prognoses for patients.
- A multicenter study analyzed the outcomes of adult patients who underwent allogeneic hematopoietic cell transplantation (HCT) in their first complete remission (CR1) for Ph-like ALL, comparing results to those of Philadelphia chromosome positive ALL (Ph-pos) and other B-cell Philadelphia negative ALL (Ph-neg).
- The findings indicated that patients with Ph-like ALL had outcomes similar to Ph-neg ALL after HCT, while Ph-pos ALL patients had significantly better survival rates, suggesting that effective second-line therapies in conjunction with HCT